首頁 > 市場調查報告書 > 醫療設備

傷口護理

創傷護理生物製藥市場規模、佔有率和成長分析（按產品類型、傷口類型、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1899688

創傷護理生物製藥市場規模、佔有率和成長分析（按產品類型、傷口類型、最終用戶和地區分類）—2026-2033年產業預測

Wound Care Biologics Market Size, Share, and Growth Analysis, By Product (Biological Skin Substitutes, Topical Agents), By Wound Type (Ulcers, Surgical & Traumatic Wounds), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球創傷護理生物製藥市場規模預計在 2024 年達到 18.8 億美元，從 2025 年的 19.8 億美元成長到 2033 年的 29.7 億美元，在預測期（2026-2033 年）內複合年成長率為 5.2%。

受技術進步和對創新癒合方案日益成長的需求驅動，全球創傷護理生物製藥市場正經歷顯著擴張。包括生長因子、細胞激素和幹細胞在內的生物製藥已被證明能有效治療慢性傷口和糖尿病潰瘍等複雜疾病。慢性病發病率的上升和人口老化導致傷口癒合延遲，是推動該市場成長的重要因素。此外，個人化醫療和先進療法的發展趨勢也促使醫療機構將生物製藥應用於臨床治療，以改善患者預後。然而，市場仍面臨許多挑戰，例如高成本限制了生物製劑的普及、嚴格的監管障礙、來自傳統治療方法的競爭，以及某些地區醫療專業人員對生物製劑認知不足等，這些都可能影響整體市場滲透率。

全球創傷護理生物製藥市場促進因素

慢性傷口（包括糖尿病足潰瘍和壓瘡）盛行率的不斷上升，在推動創傷護理生物製藥市場成長方面發揮關鍵作用。這些生物製劑提供創新有效的治療方案，能夠加速複雜傷口的癒合過程。隨著受這些疾病影響的患者人數不斷增加，對先進傷口管理解決方案的需求也日益成長，對生物製劑的需求仍然強勁。這一趨勢凸顯了創傷護理生物製藥在應對慢性創傷治療相關重大挑戰方面的重要作用。

限制全球創傷護理生物製藥市場的因素

生物創傷護理產品嚴格的監管核准流程帶來了許多挑戰，導致產品上市時間延長。這項複雜且往往耗時的程序不僅延長了創新解決方案惠及消費者的時間，也增加了製造商的研發成本。企業在應對複雜的合規和檢驗環境時，可能面臨財務限制和資源分配方面的挑戰，這會影響其競爭力以及推出新產品的能力。因此，這些監管障礙嚴重阻礙因素了全球創傷護理生物製藥市場的成長。

全球創傷護理生物製藥市場趨勢

全球創傷護理生物製藥市場正經歷著向個人化醫療的顯著轉變，這一轉變旨在根據個別患者的需求和特定的傷口特徵量身定做治療通訊協定。這種轉變反映了更廣泛的醫療保健趨勢，即優先考慮個人化治療方法並提高創傷護理干預措施的有效性。生物製藥因其能夠促進個人化癒合解決方案而日益受到認可，它們利用先進技術和生物材料來適應不同的傷口情況。隨著醫療保健提供者尋求透過標靶方法來改善患者預後，對支持個人化策略的創新創傷護理生物製藥的需求預計將顯著成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Smith & Nephew（United Kingdom）
Integra LifeSciences（United States）
Organogenesis Holdings Inc.（United States）
MiMedx Group, Inc.（United States）
Osiris Therapeutics, Inc.（United States）
Aroa Biosurgery（New Zealand）
Avita Medical（Australia）
Derma Sciences, Inc.（United States）
Alliqua BioMedical, Inc.（United States）
Amnio Technology, LLC（United States）
Tissue Regenix Group plc（United Kingdom）
CollPlant Biotechnologies Ltd.（Israel）
RenovaCare, Inc.（United States）
PolarityTE, Inc.（United States）
Cytori Therapeutics, Inc.（United States）
Histogenics Corporation（United States）
Vericel Corporation（United States）
RepliCel Life Sciences Inc.（Canada）

結論與建議

簡介目錄

Product Code: SQMIG35H2221

Global Wound Care Biologics Market size was valued at USD 1.88 Billion in 2024 and is poised to grow from USD 1.98 Billion in 2025 to USD 2.97 Billion by 2033, growing at a CAGR of 5.2% during the forecast period (2026-2033).

The global wound care biologics market is witnessing notable expansion, fueled by technological advancements and increasing demand for innovative healing solutions. Biologics, which encompass growth factors, cytokines, and stem cells, are proving effective for treating complex conditions like chronic wounds and diabetic ulcers. The rising incidence of chronic diseases and an aging population more prone to slow-healing wounds are significant contributors to this market's growth. Additionally, the trend towards personalized medicine and advanced therapies is prompting healthcare providers to integrate biologics for enhanced patient outcomes. However, challenges remain, including high costs that limit accessibility, stringent regulatory barriers, competition from traditional treatments, and insufficient awareness among healthcare professionals in certain areas, which could impact overall market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Wound Care Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Wound Care Biologics Market Segments Analysis

Global Wound Care Biologics Market is segmented by Product, Wound Type, End User and region. Based on Product, the market is segmented into Biological Skin Substitutes and Topical Agents. Based on Wound Type, the market is segmented into Ulcers, Surgical & Traumatic Wounds and Burns. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers and Burn Care Centers & Wound Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Wound Care Biologics Market

The rising prevalence of chronic wounds, including diabetic foot ulcers and pressure ulcers, plays a crucial role in propelling the growth of the wound care biologics market. These biologic products provide innovative and effective therapeutic solutions that enhance the healing process for complex wound cases. As the need for advanced wound management solutions continues to increase due to the growing patient population affected by these conditions, the demand for biologic interventions remains robust. This trend highlights the essential role that wound care biologics play in addressing the significant challenges associated with chronic wound healing.

Restraints in the Global Wound Care Biologics Market

The stringent regulatory approval process for biologic wound care products presents significant challenges that can hinder their timely market entry. This complex and often lengthy procedure not only prolongs the timeline for bringing these innovative solutions to consumers but also escalates development costs for manufacturers. As companies navigate the intricate landscape of compliance and validation, they may face financial constraints and resource allocation issues, which can affect their competitiveness and ability to introduce new products. Consequently, these regulatory hurdles serve as a notable restraint on the growth of the global wound care biologics market.

Market Trends of the Global Wound Care Biologics Market

The Global Wound Care Biologics market is experiencing a notable trend towards personalized medicine, emphasizing the customization of treatment protocols to align with individual patient needs and specific wound characteristics. This shift reflects a broader healthcare movement that prioritizes tailored therapies, enhancing the efficacy of wound care interventions. Biologics are increasingly recognized for their ability to facilitate individualized healing solutions, leveraging advanced technologies and biomaterials that adapt to diverse wound profiles. As healthcare providers seek to improve patient outcomes through targeted approaches, the demand for innovative wound care biologics that support personalized strategies is poised for significant growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Wound Care Biologics Market Size by Product & CAGR (2026-2033)

Market Overview
Biological Skin Substitutes
- Human Donor Tissue-derived Products
- Acellular Animal-derived Products
- Biosynthetic Products
Topical Agents

Global Wound Care Biologics Market Size by Wound Type & CAGR (2026-2033)

Market Overview
Ulcers
- Diabetic Foot Ulcers
- Venous Ulcers
- Pressure Ulcers
- Other Ulcers
Surgical & Traumatic Wounds
Burns

Global Wound Care Biologics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgery Centers
Burn Care Centers & Wound Clinics

Global Wound Care Biologics Market Size & CAGR (2026-2033)

North America (Product, Wound Type, End User)
- US
- Canada
Europe (Product, Wound Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Wound Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Wound Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Wound Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Smith & Nephew (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Integra LifeSciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organogenesis Holdings Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MiMedx Group, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Osiris Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aroa Biosurgery (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avita Medical (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Derma Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alliqua BioMedical, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amnio Technology, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tissue Regenix Group plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CollPlant Biotechnologies Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RenovaCare, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PolarityTE, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Histogenics Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RepliCel Life Sciences Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments